NCT00183924View on ClinicalTrials.gov

Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.

PHASE2CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

July 31, 2006

Study Completion Date

December 31, 2008

Conditions

Prostate Adenocarcinoma

Interventions

DRUG

Estramustine

DRUG

Docetaxel

DRUG

Carboplatin

Trial Locations (1)

90033

Norris Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Aventis Pharmaceuticals

All Listed Sponsors

collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

University of Southern California

OTHER